Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C25H36O6
CAS Number:
Molecular Weight:
432.55
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
237-093-4
MDL number:
InChI
1S/C25H36O6/c1-4-5-21(30)31-25(20(29)14-26)11-9-18-17-7-6-15-12-16(27)8-10-23(15,2)22(17)19(28)13-24(18,25)3/h12,17-19,22,26,28H,4-11,13-14H2,1-3H3/t17-,18-,19-,22+,23-,24-,25-/m0/s1
InChI key
BMCQMVFGOVHVNG-TUFAYURCSA-N
SMILES string
[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(OC(=O)CCC)C(=O)CO
form
solid
shipped in
ambient
storage temp.
room temp
Quality Level
Gene Information
human ... NR3C1(2908)
Application
Hydrocortisone 17-butyrate may be used:
- in the synthesis of hydrocortisone butyrate (HB)-loaded poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles
- as a topical corticosteroid (CS) to study its effects on keratinocyte proliferation in hyperproliferant keratinocytes (HaCaT) model
- in the preparation of solid lipid nanoparticles (SLN)
Biochem/physiol Actions
Hydrocortisone 17-butyrate is a corticosteroid that acts as a dermocorticoid due to its application in dermatological therapy. It exhibits therapeutic effects against vitiligo of the face and neck.
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M Caproni et al.
Clinical and experimental dermatology, 31(6), 813-817 (2006-10-17)
Topical tacrolimus represents an effective and well-tolerated treatment for atopic dermatitis (AD). Its known effects include reduced production of proinflammatory cytokines and reduced chemokine gradient. We performed lesional skin biopsies on adult patients affected by moderate-to-severe AD. Then, patients were
Lawrence Eichenfield et al.
Pediatric dermatology, 24(1), 81-84 (2007-02-16)
Corticosteroids are currently the first line of treatment for patients with atopic dermatitis. In the pediatric population however, the potential impact of adrenal suppression is always an important safety concern. Twenty boys and girls, 5-12 years of age, with normal
S Reitamo et al.
The British journal of dermatology, 152(6), 1282-1289 (2005-06-14)
Atopic dermatis (AD) is a chronic disease that often requires long-term treatment. Topical corticosteroids are the usual therapy for patients with AD, but prolonged usage can result in skin atrophy and other side-effects. In a randomized, double-blind, comparative study, to
F Sassi et al.
The British journal of dermatology, 159(5), 1186-1191 (2008-08-23)
Vitiligo is a pigmentary disorder which may have disfiguring consequences. Its treatment remains a challenge. We designed a parallel-group randomized controlled trial to compare the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in
Hidemi Nakagawa
Clinical drug investigation, 26(5), 235-246 (2006-12-14)
Tacrolimus (FK506) ointment is widely used in the treatment of patients with atopic dermatitis. The drug exerts its action by down-regulating antigen-specific T-cell activities and associated proinflammatory cytokine production. A number of clinical studies have evaluated the efficacy and safety
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service